Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation by E. Favi et al.
World Journal of
Clinical Cases
World J Clin Cases  2019 February 6; 7(3): 260-404
ISSN 2307-8960 (online)
Published by Baishideng Publishing Group Inc
W J C C World Journal ofClinical Cases
Contents Semimonthly  Volume 7  Number 3  February 6, 2019
ORIGINAL ARTICLE
Retrospective Cohort Study
260 Overexpression of HSP27 and HSP70 is associated with decreased survival among patients with esophageal
adenocarcinoma
Söderström HK, Kauppi JT, Oksala N, Paavonen T, Krogerus L, Räsänen J, Rantanen T
Observational Study
270 Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation
Favi E, Puliatti C, Sivaprakasam R, Ferraresso M, Ambrogi F, Delbue S, Gervasi F, Salzillo I, Raison N, Cacciola R
291 Influencing factors of postoperative early delayed gastric emptying after minimally invasive Ivor-Lewis
esophagectomy
Huang L, Wu JQ, Han B, Wen Z, Chen PR, Sun XK, Guo XD, Zhao CM
Prospective Study
300 Split-dose or hybrid nonsteroidal anti-inflammatory drugs and N-acetylcysteine therapy for prevention of
post-retrograde cholangiopancreatography pancreatitis
Pavel L, Bălan GG, Nicorescu A, Gîlcă-Blanariu GE, Sfarti C, Chiriac Ș, Diaconescu S, Drug VL, Bălan G, Ștefănescu G
SYSTEMATIC REVIEWS
311 Celiac crisis, a rare occurrence in adult celiac disease: A systematic review
Balaban DV, Dima A, Jurcut C, Popp A, Jinga M
META-ANALYSIS
320 Hand-assisted laparoscopic splenectomy is a useful surgical treatment method for patients with excessive
splenomegaly: A meta-analysis
Huang Y, Wang XY, Wang K
CASE REPORT
335 Successful treatment of obstructing colonic cancer by combining self-expandable stent and neoadjuvant
chemotherapy: A case report
Li ZL, Wang ZJ, Han JG, Yang Y
340 Long-term survival of a patient with a large adrenal primitive neuroectodermal tumor: A case report
Dai J, He HC, Huang X, Sun FK, Zhu Y, Xu DF
347 Intravenous leiomyomatosis with different surgical approaches: Three case reports
He J, Chen ZB, Wang SM, Liu MB, Li ZG, Li HY, Zhao G
WJCC https://www.wjgnet.com February 6, 2019 Volume 7 Issue 3I
Contents
World Journal of Clinical Cases
Volume 7  Number 3  February 6, 2019
357 Ghost cell odontogenic carcinoma of the jaws: Report of two cases and a literature review
Jia MQ, Jia J, Wang L, Zou HX
366 Papillary cystadenoma of the parotid gland: A case report
Wang L, Zhang SK, Ma Y, Ha PK, Wang ZM
373 Castleman disease presenting with jaundice: A case report and review of literature
Zhai B, Ren HY, Li WD, Reddy S, Zhang SJ, Sun XY
382 Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the
literature
Wu HD, Cao HY, Song ZK, Yang S, Tang ML, Liu Y, Qin L
389 Gerstmann-Sträussler-Scheinker disease: A case report
Zhao MM, Feng LS, Hou S, Shen PP, Cui L, Feng JC
396 Biventricular pacing for treating heart failure in children: A case report and review of the literature
Yu S, Wu Q, Chen BL, An YP, Bu J, Zhou S, Wang YM
WJCC https://www.wjgnet.com February 6, 2019 Volume 7 Issue 3II
Contents
World Journal of Clinical Cases
Volume 7  Number 3  February 6, 2019
ABOUT COVER Editorial Board Member of World Journal of Clinical Cases, Shui-Bo Zhu, MD,
PhD, Professor, Department of Thoracic Cardiovascular Surgery, Wuhan
Military Command Wuhan General Hospital, Wuhan 430070, Hubei
Province, China
AIMS AND SCOPE World Journal of Clinical Cases (World J Clin Cases, WJCC, online ISSN 2307-
8960, DOI: 10.12998) is a peer-reviewed open access academic journal that
aims to guide clinical practice and improve diagnostic and therapeutic skills
of clinicians.
    The primary task of WJCC is to rapidly publish high-quality Case Report,
Clinical Management, Editorial, Field of Vision, Frontier, Medical Ethics,
Original Articles, Meta-Analysis, Minireviews, and Review, in the fields of
allergy, anesthesiology, cardiac medicine, clinical genetics, clinical
neurology, critical care, dentistry, dermatology, emergency medicine,
endocrinology, family medicine, gastroenterology and hepatology, etc.
INDEXING/ABSTRACTING World Journal of Clinical Cases (WJCC) is now indexed in PubMed, PubMed Central,
Science Citation Index Expanded (also known as SciSearch®), and Journal Citation
Reports/Science Edition. The 2018 Edition of Journal Citation Reports cites the 2017
impact factor for WJCC as 1.931 (5-year impact factor: N/A), ranking WJCC as 60
among 154 journals in Medicine, General and Internal (quartile in category Q2).
RESPONSIBLE EDITORS
FOR THIS ISSUE Responsible Electronic Editor: Han Song Proofing Editorial Office Director: Jin-Lei Wang
NAME OF JOURNAL
World Journal of Clinical Cases
ISSN
ISSN 2307-8960 (online)
LAUNCH DATE
April 16, 2013
FREQUENCY
Semimonthly
EDITORS-IN-CHIEF
Dennis A Bloomfield, Sandro Vento
EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm
EDITORIAL OFFICE
Jin-Lei Wang, Director
PUBLICATION DATE
February 6, 2019
COPYRIGHT
© 2019 Baishideng Publishing Group Inc
INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204
GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287
GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240
PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208
ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242
STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/GerInfo/239
ONLINE SUBMISSION
https://www.f6publishing.com
© 2019 Baishideng Publishing Group Inc. All rights reserved. 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
E-mail: bpgoffice@wjgnet.com  https://www.wjgnet.com
WJCC https://www.wjgnet.com February 6, 2019 Volume 7 Issue 3III
W J C C World Journal ofClinical Cases
Submit a Manuscript: https://www.f6publishing.com World J Clin Cases  2019 February 6; 7(3): 270-290
DOI: 10.12998/wjcc.v7.i3.270 ISSN 2307-8960 (online)
ORIGINAL ARTICLE
Observational Study
Incidence, risk factors, and outcome of BK polyomavirus infection
after kidney transplantation
Evaldo Favi, Carmelo Puliatti, Rajesh Sivaprakasam, Mariano Ferraresso, Federico Ambrogi, Serena Delbue,
Federico Gervasi, Ilaria Salzillo, Nicholas Raison, Roberto Cacciola
ORCID number: Evaldo Favi
(0000-0001-6465-428X); Carmelo
Puliatti (0000-0001-7398-2648);
Rajesh Sivaprakasam
(0000-0002-6145-4642); Mariano
Ferraresso (0000-0003-3410-9090);
Federico Ambrogi
(0000-0001-9358-011X); Serena
Delbue (0000-0002-3199-9369);
Federico Gervasi
(0000-0003-4539-5010); Ilaria Salzillo
(0000-0001-7560-7614); Nicholas
Raison (0000-0003-0496-4985);
Roberto Cacciola
(0000-0001-8363-1358).
Author contributions: Favi E, data
collection, data analysis, data
interpretation, drafting the article,
critical revision, and final
approval; Puliatti C, conception of
the study, design of the study,
critical revision, and final
approval; Sivaprakasam R, design
of the study, data collection, data
interpretation, critical revision, and
final approval; Ferraresso M, data
interpretation, critical revision, and
final approval; Ambrogi F, data
analysis, data interpretation,
drafting the article, critical
revision, and final approval;
Delbue S, data interpretation,
critical revision, and final
approval; Gervasi F, data analysis,
data interpretation, drafting the
article, and final approval; Salzillo
I, data collection, editing the
article, and final approval;
Nicholas Raison, drafting the
article, language revision, critical
revision, and final approval;
Cacciola R, conception of the
study, design of the study, data
collection, critical revision, and
final approval.
Evaldo Favi, Mariano Ferraresso, Ilaria Salzillo, Renal Transplantation, Fondazione IRCCS Ca’
Granda Ospedale Maggiore Policlinico, Milan 20122, Italy
Carmelo Puliatti, Rajesh Sivaprakasam, Roberto Cacciola, Renal Transplantation, Barts Health
NHS Trust, Royal London Hospital, London E1 1BB, United Kingdom
Mariano Ferraresso, Federico Ambrogi, Federico Gervasi, Department of Clinical Sciences and
Community Health, University of Milan, Milan 20122, Italy
Serena Delbue, Department of Biomedical, Surgical and Dental Sciences, University of Milan,
Milan 20100, Italy
Nicholas Raison, MRC Centre for Transplantation, King’s College London, London WC2R
2LS, United Kingdom
Corresponding author: Evaldo Favi, MD, PhD, Senior Lecturer, Surgeon, Renal
Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via
Francesco Sforza n. 28, Milan 20122, Italy. evaldofavi@gmail.com
Telephone: +39-2-55035603
Fax: +39-2-55035630
Abstract
BACKGROUND
Polyomavirus-associated nephropathy is a leading cause of kidney allograft
failure. Therapeutic options are limited and prompt reduction of the net state of
immunosuppression represents the mainstay of treatment. More recent
application of aggressive screening and management protocols for BK-virus
infection after renal transplantation has shown encouraging results. Nevertheless,
long-term outcome for patients with BK-viremia and nephropathy remains
obscure. Risk factors for BK-virus infection are also unclear.
AIM
To investigate incidence, risk factors, and outcome of BK-virus infection after
kidney transplantation.
METHODS
This single-centre observational study with a median follow up of 57 (31-80) mo
comprises 629 consecutive adult patients who underwent kidney transplantation
between 2007 and 2013. Data were prospectively recorded and annually reviewed
until 2016. Recipients were periodically screened for BK-virus by plasma
WJCC https://www.wjgnet.com February 6, 2019 Volume 7 Issue 3
270
Institutional review board
statement: This study was
discussed in a regular Research
Meeting at The Royal London
Hospital and the consensus was
that ethical approval was not
required because of the
observational nature and non-
interventional study design.
Informed consent statement:
Patients were all consented at the
time of activation on the national
transplant waiting list. They were
aware that their anonymized data
including viral status as well as
other biomedical parameters
would have been used for research
purpose.
Conflict-of-interest statement: The
authors do not have any conflicting
interests.
Data sharing statement: Dataset
available from the corresponding
author at evaldofavi@gmail.com.
Informed consent for data sharing
outside formal research projects
was not obtained but data are
anonymized and there is no risk of
patient details identification.
STROBE statement: The authors
have read the STROBE
Statement–checklist of items, and
the manuscript was prepared and
revised according to the STROBE
Statement–checklist of items.
Open-Access: This article is an
open-access article which was
selected by an in-house editor and
fully peer-reviewed by external
reviewers. It is distributed in
accordance with the Creative
Commons Attribution Non
Commercial (CC BY-NC 4.0)
license, which permits others to
distribute, remix, adapt, build
upon this work non-commercially,
and license their derivative works
on different terms, provided the
original work is properly cited and
the use is non-commercial. See:
http://creativecommons.org/licen
ses/by-nc/4.0/
Manuscript source: Invited
manuscript
Received: October 31, 2018
Peer-review  started:  October  31,
2018
First decision: November 27, 2018
Revised: December 8, 2018
Accepted: December 12, 2018
Article in press: December 12, 2018
Published online: February 6, 2019
quantitative polymerized chain reaction. Patients with BK viral load ≥ 1000
copies/mL were diagnosed BK-viremia and underwent histological assessment
to rule out nephropathy. In case of BK-viremia, immunosuppression was
minimized according to a prespecified protocol. The following outcomes were
evaluated: patient survival, overall graft survival, graft failure considering death
as a competing risk, 30-d-event-censored graft failure, response to treatment,
rejection, renal function, urologic complications, opportunistic infections, new-
onset diabetes after transplantation, and malignancies. We used a multivariable
model to analyse risk factors for BK-viremia and nephropathy.
RESULTS
BK-viremia was detected in 9.5% recipients. Initial viral load was high (≥ 10000
copies/mL) in 66.7% and low (< 10000 copies/mL) in 33.3% of these patients.
Polyomavirus-associated nephropathy was diagnosed in 6.5% of the study
population. Patients with high initial viral load were more likely to experience
sustained viremia (95% vs 25%, P < 0.00001), nephropathy (92.5% vs 15%, P <
0.00001), and polyomavirus-related graft loss (27.5% vs 0%, P = 0.0108) than
recipients with low initial viral load. Comparison between recipients with or
without BK-viremia showed that the proportion of patients with Afro-Caribbean
ethnicity (33.3% vs 16.5%, P = 0.0024), panel-reactive antibody ≥ 50% (30% vs
14.6%, P = 0.0047), human leukocyte antigen (HLA) mismatching > 4 (26.7% vs
13.4%, P = 0.0110), and rejection within thirty days of transplant (21.7% vs 9.5%; P
= 0.0073) was higher in the viremic group. Five-year patient and overall graft
survival rates for patients with or without BK-viremia were similar. However,
viremic recipients showed higher 5-year crude cumulative (22.5% vs 12.2%, P =
0.0270) and 30-d-event-censored (22.5% vs 7.1%, P = 0.001) incidences of graft
failure than control. In the viremic group we also observed higher proportions of
recipients with 5-year estimated glomerular filtration rate < 30 mL/min than the
group without viremia: 45% vs 27% (P = 0.0064). Urologic complications were
comparable between the two groups. Response to treatment was complete in
55%, partial in 26.7%, and absent in 18.3% patients. The nephropathy group
showed higher 5-year crude cumulative and 30-d-event-censored incidences of
graft failure than control: 29.1% vs 12.1% (P = 0.008) and 29.1% vs 7.2% (P <
0.001), respectively. Our multivariable model demonstrated that Afro-Caribbean
ethnicity, panel-reactive antibody > 50%, HLA mismatching > 4, and rejection
were independent risk factors for BK-virus viremia whereas cytomegalovirus
prophylaxis was protective.
CONCLUSION
Current treatment of BK-virus infection offers sub-optimal results. Initial viremia
is a valuable parameter to detect patients at increased risk of nephropathy. Panel-
reactive antibody > 50% and Afro-Caribbean ethnicity are independent predictors
of BK-virus infection whereas cytomegalovirus prophylaxis has a protective
effect.
Key words: Polyomavirus; BK virus; Kidney transplantation; Outcome; Risk factors;
Immunosuppression; Human leukocyte antigen; Rejection; Cytomegalovirus; Ethnicity
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Polyomavirus-associated nephropathy is a leading cause of kidney transplant
failure. A systematic screening and treatment protocol in line with current international
guideline was evaluated. Our results showed that despite early diagnosis and prompt
intervention, graft-related outcomes for patients with BK-virus infection remain
substantially inferior to control. We confirmed that initial viral load ≥ 10000 copies/mL
is highly predictive of nephropathy. New putative risk factors for BK-viremia and
nephropathy were also identified. Properly designed large multi-centre studies are
warranted to further investigate individual susceptibility to BK-virus infection and
validate alternative antiviral therapies.
Citation: Favi E, Puliatti C, Sivaprakasam R, Ferraresso M, Ambrogi F, Delbue S, Gervasi F,
Salzillo I, Raison N, Cacciola R. Incidence, risk factors, and outcome of BK polyomavirus
infection after kidney transplantation. World J Clin Cases 2019; 7(3): 270-290
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INTRODUCTION
Kidney transplantation is the best treatment option for patients with end-stage renal
disease[1]. However, due to chronic exposure to powerful immunosuppressive agents,
transplant recipients have a greater risk of cardiovascular disease, malignancies, and
infections  than  the  general  population [2].  Polyomavirus  infection  is  serious
complication of immunosuppression as it is recognized as a leading cause of impaired
graft function and premature transplant loss[3].
There are three main members of the polyomavirus family infecting humans: BK-
virus (BKV), JC-virus, and Merkel cell polyomavirus. The majority of the infections
following kidney transplantation  are  attributed to  BKV.  An ubiquitous  double-
stranded DNA pathogen, it is usually contracted during childhood[4] and is detectable
in up to 80% of adults undergoing serological screening[5]. Following contact with the
host, the virus reaches the kidney via haematogenous spread where it establishes a
latent or sub-lytic infection in the tubular cells[6]. In immunocompromised individuals,
the virus can undergo uncontrolled replication causing cell lysis and necrosis through
direct and indirect mechanisms[7]. In the allograft, this process may eventually lead to
irreversible tissue damage and progressive loss of function[8].
Immunosuppression  is  considered  the  most  important  risk  factor  for  post-
transplant  BKV  infection [9].  Nevertheless,  more  recent  evidence  shows  that
interactions between immunosuppressive drugs and BKV are not as simple as initially
postulated[10-12]. Clinical practice has also evolved and current data may not reflect
previous reports in the literature.
There  is  still  no  consensus  in  the  transplant  community  regarding  the  best
screening and treatment strategies for BKV infection or polyomavirus-associated
nephropathy (PVAN). Most authors recommend periodic assessment by quantitative
polymerized chain reaction (qPCR) analysis of blood samples but target population,
exact timing, and length of the screening program remain debated[13-15]. Reducing the
net state of immunosuppression is the mainstay of treatment[16].  Dose adjustment,
drug withdrawal, or substituting agents have been proposed with mixed results[13].
Proliferation signal inhibitors (i.e. sirolimus and everolimus) have shown encouraging
results but solid evidence is missing[17]. Unfortunately, benefits arising from antiviral
therapies such as cidofovir, quinolones, leflunomide or intravenous immunoglobulin
remain controversial. Sub-optimal results have been reported and efficacy is overall
limited by drug-induced nephrotoxicity and side effects[18].
Since 2007, we have been enforcing a strict surveillance policy and a step by step
management strategy for BKV infection in all kidney transplant recipients followed
up at our centre. This experience is herein reported.
MATERIAL AND METHODS
Study design and objectives
In this single-centre observational cohort study we enrolled adult patients who had
undergone kidney transplantation at  The Royal  London Hospital  (London,  UK),
between April 2007 and March 2013. Considering previous studies on the same topic,
a minimum sample size of 400 subjects was established. Inclusion criteria were: living
or deceased donor kidney transplant and recipient age ≥ 18 years. Recipients of other
solid organ transplants or the second kidney transplant for those transplanted twice
during  the  study  period  were  excluded.  Donor  data,  organ  details,  recipient
characteristics, and transplant outcomes were prospectively recorded on a central
database as per standard practice at our institution by dedicated staff and annually
reviewed by the authors until June 2016. Patients were all consented at the time of
activation on the national transplant waiting list. According to Barts Health NHS
Trust General Data Protection Act, General Data Protection and Regulation 2016, and
Data Protection Act 2018, they were aware that their anonymized data including viral
status as well as other biomedical parameters would have been used for research
purpose.  Patients  who  did  not  want  their  personal  information  to  be  used  for
planning and research were given the possibility to express their preference under the
National Data Opt-out Programme. Based on the observational nature of the study
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and given the  fact  that  no off-label  medications  were  used to  treat  BKV-related
complications, the protocol was not reviewed by our Ethical Committee. The study
was conducted according to the World Medical Association Declaration of Helsinki
and applicable regulatory requirements.
After transplantation, all patients were screened for BKV replication by plasma
qPCR.  The  test  was  performed  every  two  weeks  during  the  first  three  months,
monthly from month three to month six, every two months from month six to month
twelve, and during investigation of worsening graft function (i.e. serum creatinine
concentration increase ≥ 30% from nadir) thereafter. Recipients with BKV plasma
qPCR ≥ 1000 copies/mL were diagnosed BKV viremia and were further assessed by
allograft histology (ultrasound-guided biopsy). Initial viral load was classified as high
(≥ 10000 copies/mL) or low (< 10000 copies/mL). Episodes of viremia were defined as
early (< 180 d from transplant) or late (≥ 180 d from transplant) and as transient (< 3
consecutive weeks) or sustained (≥ 3 consecutive weeks). Patients with viremia and
positive histology were diagnosed PVAN. PVAN was always confirmed by SV40
immunohistochemistry[19].
Recipients  with BKV viremia (regardless  of  symptoms or  histology)  had their
immunosuppressive  therapy progressively  modified according to  the  following
scheme:  (1)  50% reduction of  mycophenolate mofetil  (MMF) or  azathioprine;  (2)
withdrawal of MMF or azathioprine; (3) 30% reduction of cyclosporine or tacrolimus;
(4) 50% reduction of cyclosporine or tacrolimus; and (5) switch from tacrolimus to
cyclosporine. Sequential changes were made every two weeks according to clinical
findings.  Response  to  treatment  was  defined as:  (a)  Complete  (no  viremia  with
restored graft  function);  (b) partial  (no viremia with permanently impaired graft
function); and (c) absent (persistent viremia with progressive graft failure due to
PVAN).
Aim of the present study was to assess incidence, risk factors, and outcome of BKV
viremia and PVAN in a cohort  of  kidney transplant  recipients  managed using a
systematic  anti-BKV protocol.  The following outcome measures  were evaluated:
patient survival, overall graft survival, graft failure considering death without graft
failure as a competing risk, 30-d-event-censored graft failure (excluding any graft
losses recorded within thirty days of  transplant),  biopsy-proven rejection (BPR),
proportion of patients with 5-year Modification of Diet in Renal Disease (MDRD)[20]
estimated glomerular filtration rate (eGFR) < 30 mL/min per 1.73 m2, response to
reduction of the net state of immunosuppression, urologic complications (ureteral
leakage or stenosis), opportunistic infections, new-onset diabetes after transplantation
(NODAT), and malignancies. Results were compared between groups.
Relationships between BKV-related clinical findings (i.e. onset of viremia, initial
viral load, duration of viremia or allograft histology) and course of the infection were
also investigated.
Risk  factors  analysis  for  BKV viremia  and PVAN included:  donor  age,  donor
gender, donor-recipient human leukocyte antigen (HLA) mismatching (cumulative,
HLA-A, HLA-B, and HLA-DR), panel-reactive antibody (PRA) test (≤ 50% vs > 50%),
cold  ischemia  time,  recipient  age,  recipient  gender,  donor-recipient  gender
mismatching, recipient ethnicity (Caucasian vs Afro-Caribbean), recipient body mass
index, dialysis modality, pre-transplant diabetes, cytomegalovirus (CMV) donor-
recipient immunization, CMV prophylaxis, delayed graft function (DGF), and BPR
within thirty days of transplant.
Primary  non-function  (PNF)  was  defined  as  graft  function  unable  to  prevent
continued renal replacement therapy or requiring re-transplantation when surgical
causes  of  renal  failure  or  rejection  were  excluded  (by  imaging,  exploration  or
histology).  DGF was defined as  the need for  dialysis  during the first  week after
surgery. Diagnosis of rejection was based on serum creatinine concentration increase
≥ 30% from nadir and always confirmed by histology (BPR)[21]. Renal function was
measured by serum creatinine concentration (mmol/L) and MDRD eGFR formula.
NODAT was diagnosed using the American Diabetes Association criteria (updated in
2003) for the diagnosis of diabetes mellitus[22].
Immunosuppression
As induction treatment, patients received intravenous (IV) methylprednisolone (500
mg on day 0, 250 mg on day 1, and 125 mg on day 2) in association with one of the
following:  (1)  IV  rabbit  anti-thymocyte  globulin  (Thymoglobulin®,  Genzyme,
Cambridge, MA) 1 mg/kg/day from day 0 to day 4; (2) IV basiliximab (Simulect®,
Novartis,  Basel,  Switzerland)  20  mg  on  days  0  and  day  4;  (3)  IV  daclizumab
(Zenapax®, Roche, Basel, Switzerland) 1mg/kg on days 0, 14, 28, 42, and 56; (4) IV
rituximab (Rituxan®, Genentech, San Francisco, CA) 375 mg/m2 three weeks before
transplant  plus  intravenous  basiliximab  20  mg  on  days  0  and  day  4;  (5)  IV
alemtuzumab (Campath®, Millennium and ILEX Partners, Cambridge, MA) 30 mg on
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day  0;  or  (6)  IV  muromonab-CD3  (Orthoclone  OKT®3,  Centocor  Ortho  Biotech
Products, Raritan, NJ) 5 mg/kg/day from day 0 to day 7.
As  maintenance  immunosuppression,  we  administered  one  of  the  following
combinations: (1) cyclosporine, MMF, and steroids; (2) cyclosporine, azathioprine, and
steroids; (3) tacrolimus, MMF, and steroids; d) tacrolimus, azathioprine, and steroids;
(4) cyclosporine and MMF; or (5) tacrolimus and azathioprine. Cyclosporine (Neoral®,
Novartis, Basel, Switzerland) was orally given 5 mg/kg twice a day from day 0 and
the dose was adjusted to achieve a target trough level of 200 ng/mL during the first
month  and  150-100  ng/mL  thereafter.  Tacrolimus  (Prograf®,  Astellas  Pharma,
Deerfield, IL) was administered orally 0.1 mg/kg twice daily from day 0 and the dose
was adjusted to achieve a target trough level of 8-12 ng/mL during the first month
and 5-8 ng/mL thereafter. MMF (Myfenax®, Teva, Petach Tikva, Israel) was orally
given 1000 mg twice a day from day 0. In Afro-Caribbean patients MMF daily dose
was increased to 3000 mg. Azathioprine (Imuran®,  Prometheus Laboratories,  San
Diego, CA) was orally administered 5 mg/kg per day from day 0. Prednisone was
orally given 20 mg/d starting on day 3 and progressively tapered to 5 mg a day after
one month of follow up.
Concomitant medications
Patients were all given prophylaxis for pneumocystis jirovecii pneumonia with oral
trimethoprim/sulfamethoxazole  160-800  mg  every  other  day  for  three  months.
Recipients at increased risk of CMV disease (i.e. donor CMV positive/recipient CMV
negative immunization, rabbit anti-thymocyte globulin induction or anti-rejection
treatment) also received antiviral prophylaxis with oral valganciclovir (dose titrated
according to renal function) for six months.
Statistical analysis
Categorical and ordinal outcomes were described using proportions, medians, 1st-3rd
interquartile range and were compared using Fisher’s exact, Chi-square or Mann-
Whitney U  test  as  appropriate.  Patient  survival  and overall  graft  survival  were
analyzed with the Kaplan-Meier method. Survival curves were compared with log-
rank. Graft failure was also analysed considering death without graft failure as a
competing risk. The same analysis was conducted excluding any graft failures within
thirty days of transplant (30-d-event-censored graft failure). Gray’s test was used to
compare the crude cumulative incidence curves. Competing risks were also used to
estimate the crude cumulative incidence of BKV viremia and PVAN. We assessed the
association of a pool of variables with the risk of BKV viremia and PVAN. According
to standard guidelines on the number of variables that can be considered in relation to
the dependent variables (at least 5 events per variable), a maximum of 12 variables for
BKV viremia and of 4 variables for PVAN could be considered. According to this
requirement, a mild univariate screening for covariates having a P-value < 0.8 for
viremia and < 0.5 for PVAN was used for building the multivariable models. Primary
renal disease, renal replacement therapy, donor type, induction, and maintenance
immunosuppression were not considered. Continuous variables were dichotomized
according to generally accepted cut-off values. Moreover, only HLA mismatching > 4
was considered among the HLA-related variables. We chose a backward method
based on AIC criterion to select significant independent covariates. Bootstrap was
used to evaluate the stability of the results by counting the percentage of bootstrap
samples for which each covariate was selected. Bootstrap with variable selection was
also used to estimate a C-index corrected for optimism. Odds ratios, and 95%CI were
reported for  variables  in  the final  model.  The same strategy was used in PVAN
analysis, excluding viral load. Penalized regression (Firth) was used to estimate the
association with viral load, as almost perfect separation was present. We performed
analyses with R software[23]. The statistical methods of this study were reviewed by a
senior  biomedical  statistician  (Federico  Ambrogi,  Associate  Professor  from  the
Laboratory of Medical Statistics, Biometrics and Epidemiology of the Department of
Clinical Sciences and Community Health of the University of Milan).
RESULTS
Study cohort
From April 2007 to March 2013, we performed 639 consecutive kidney transplants in
633 patients. According to our inclusion/exclusion criteria, 629/633 (99.4%) subjects
were enrolled into the study. Reasons for exclusion were recipient age < 18 years (n =
2) and previous liver transplant (n = 2).
Three-hundred-ninety-five/629 (62.8%) patients received a kidney from a deceased
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donor (263/395, 66.6% DBD; 132/395, 33.4% DCD) and 234/629 (37.2%) from a living
donor (153/234, 65.4% related; 81/234, 34.6% unrelated). Median recipient and donor
age were 47 (36-55) and 48 (39-57) years whereas median HLA mismatching and cold
ischemia time were 3 (2-4) and 12 (4-16) h, respectively. Baseline recipient, donor, and
transplant-related data of the study cohort are detailed in Table 1.
Seventy-three/629 (11.6%) recipients were transferred to other institutions before
study completion (38/73, 52% within one year of transplant). Median follow up was
57 (31-80) mo. No patients were excluded from the analysis (intention to treat).
Transplant outcomes
One-year and 5-year patient survival rates were 93.7% (95%CI: 91.5%-95.3%) and
88.5% (95%CI:  85.5%-90.9%),  respectively.  During the follow up,  68/629 (10.8%)
recipients died. The following causes of death were recorded: sepsis (n = 32), sudden
cardiac death (n = 14), malignancy (n = 5), post-operative surgical complication (n =
3), sclerosing peritonitis (n = 3), myocardial infarction (n = 3), oesophageal variceal
bleeding (n  =  2),  stroke (n  =  2),  heart  failure  (n  =  1),  ruptured abdominal  aortic
aneurysm (n = 1), and unknown (n = 2).
One-year  and  5-year  crude  cumulative  incidences  of  graft  failure  were  7.1%
(95%CI: 5.0%-9.8%) and 13.3% (95%CI: 10.5%-16.0%), respectively. During the study,
131/629 (20.8%) transplant losses were observed. As shown in Figure 1, reasons for
graft loss were: death with function (n = 49), chronic allograft injury (n = 14), PNF (n =
12), renal vein thrombosis (n = 11), PVAN (n = 11), BPR (n = 11), recurrent primary
renal disease (n = 7), allograft pyelonephritis (n = 7), renal artery thrombosis (n = 4),
atypical  haemolytic  uremic  syndrome  (n  =  1),  calcineurin  inhibitor-induced
haemolytic uremic syndrome (n = 1), septic shock (n = 1), post-operative bleeding (n =
1), and prophylactic allograft nephrectomy due to donor malignancy (n = 1).
PNF and DGF rates were 12/629 (1.9%) and 169/629 (26.9%), respectively. One-
year  BPR  rate  was  151/629  (24%)  with  a  median  time  from  transplant  to  BPR
(considering patients with rejection only) equal to 25 (7-93) d. Donor-specific antibody
were detected in 98/629 (15.6%) recipients.
Incidence of BKV viremia and PVAN
BKV viremia (BKV plasma qPCR ≥ 1000 copies/mL) was detected in 60/629 (9.5%)
patients. Median time from transplant to first diagnosis of viremia (considering the
infected  patients  only)  was  152  (84-346)  d.  Within  180  d  of  transplant,  crude
cumulative incidence of BKV viremia was 5.0% (95%CI: 3.5%-7.0%) with 33 episodes
recorded. Crude cumulative incidence of BKV viremia during the follow up is shown
in Figure 2. At the time of diagnosis,  graft function was normal in 10/60 (16.7%)
recipients  and  impaired  in  50/60  (83.3%).  Initial  viral  load  was  high  (≥  10000
copies/mL) in 40/60 (66.7%) cases and low (< 10000 copies/mL) in 20/60 (33.3%).
Viral replication was transient (< 3 wk) in 17/60 (28.3%) patients whereas it  was
sustained  (≥  3  wk)  in  43/60  (71.7%).  PVAN  (allograft  biopsy  positive  to  SV40
immunostaining) was diagnosed in 40/60 (66.7%) recipients with viremia. Crude
cumulative incidence of PVAN in the study cohort was 6.5% (95%CI: 4.6%-8.5%) with
40 events recorded.
We could not demonstrate any relationships between onset of viremia (< 180 d vs ≥
180 d after transplant) and initial viral load (low vs high), duration of viremic phase
(transient  vs.  sustained),  PVAN  or  BKV-related  graft  failure.  Nevertheless,  we
observed that patients with high initial viral load were more likely to experience
sustained viremia (38/40, 95% vs 5/20, 25%, P < 0.00001), PVAN (37/40, 92.5% vs
3/20, 15%, P < 0.00001), and BKV-related graft loss (11/40, 27.5% vs 0/20, 0%, P =
0.0108) than recipients with low initial viral load. Accordingly, comparison between
patients with transient or sustained viremia showed that the proportion of patients
with initial viral load ≥ 10000 copies/mL was significantly higher in the group with
prolonged viral replication (38/43, 88.4% vs  2/17, 11.8%, P  < 0.00001).  Sustained
viremia was also associated with higher rate of PVAN (38/43, 88.4% vs 2/17, 11.8%, P
< 0.00001) and BKV-related graft failure (11/43, 25.6% vs 0/17, 0%, P = 0.0247).
Comparison of characteristics of the recipients experiencing BKV viremia or not
(Table  2)  showed that  the  proportion  of  patients  with  Afro-Caribbean ethnicity
(20/60, 33.3% vs 94/569, 16.5%, P = 0.0024), PRA test ≥ 50% (18/60, 30% vs 83/569,
14.6%, P = 0.0047), HLA mismatch > 4 (16/60, 26.7% vs 76/569, 13.4%, P = 0.0110), and
BPR within thirty days of transplant (13/60, 21.7% vs 54/569, 9.5%, P = 0.0073) was
significantly higher in the viremic group than control. We also observed a significant
difference in median donor age (No BKV: 47, 38-57 vs BKV: 51.5, 40.75-60.25 years, P =
0.0483)  and  HLA-DR  mismatch  (No  BKV:  1,  0-1  vs  BKV:  0-1.25,  P  =  0.0482).
Distributions of  induction and maintenance immunosuppression therapies  were
similar. Subanalysis of baseline characteristics of viremic patients with or without
PVAN were not significantly different (Table 3).
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Table 1  Donor, transplant, and recipient characteristics of the study population
Variables Median (IQR) or n (%)
Patients 629
Recipient Male : Female 372:257
Caucasian ethnicity 279/629 (44.3)
Afro-Caribbean ethnicity 114/629 (18.1)
Recipient age (yr) 47 (36-55)
Recipient body mass index (kg/m²) 25.2 (22.2-27.5)
Pre-transplant diabetes 83/629 (13.2)
Pre-transplant cardiovascular disease 62/629 (9.9)
Recipient cytomegalovirus IgG positive 431/629 (68.5)
Glomerular disease 185/629 (29.4)
Polycystic kidney disease 71/629 (11.3)
Tubular-interstitial nephropathy 81/629 (12.9)
Diabetic nephropathy 49/629 (7.8)
Hypertension 55/629 (8.7)
Unknown renal disease 141/629 (22.4)
Other renal disease 47/629 (7.5)
Haemodialysis 295/629 (46.9)
Peritoneal dialysis 136/629 (21.6)
Peritoneal dialysis and haemodialysis 118/629 (18.8)
Pre-emptive transplant 80/629 (12.7)
Panel-reactive antibody > 50% 101/629 (16.1)
Primary transplant 550/629 (87.4)
Deceased donor 395/629 (62.8)
Donation after brain death donor 263/629 (41.8)
ABO-incompatible transplant 25/629 (4.0)
Donor age (yr) 48 (39-57)
Donor-recipient gender mismatch 340/629 (54.1)
Donor cytomegalovirus IgG positive 354/629 (56.3)
Cytomegalovirus D+R- immunization 83/629 (13.2)
Cold ischemia time (hours) 12 (4-16)
Cold ischemia time >12 h 282/629 (44.8)
Cumulative HLA mismatch 3 (2-4)
HLA mismatch > 4 92/629 (14.6)
Induction treatment
Anti-IL2-receptor antagonist 431/629 (68.5)
Rabbit anti-thymocyte globulin 169/629 (26.9)
Rituximab 25/629 (4.0)
Alemtuzumab 3/629 (0.5)
Muromonab-CD3 1/629 (0.2)
Maintenance immunosuppression
CyA-MMF-steroid 422/629 (67.1)
CyA-AZA-steroid 3/629 (0.5)
Tacrolimus-MMF-steroid 109/629 (17.3)
Tacrolimus-AZA-steroid 79/629 (12.6)
Tacrolimus-MMF 12/629 (1.9)
Tacrolimus-AZA 2/629 (0.3)
AZA-MMF-steroid 1/629 (0.2)
AZA-steroid 1/629 (0.2)
CyA-based scheme 425/629 (67.6)
Tacrolimus-based scheme 202/629 (32.1)
CNI-free scheme 2/629 (0.3)
MMF-containing scheme 544/629 (86.5)
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AZA-containing scheme 86/629 (13.7)
Steroid-free scheme 14/629 (2.2)
Cytomegalovirus prophylaxis 241/629 (38.3)
IQR: Interquartile range; IgG: Immunoglobulin class G; HLA: Human leukocyte antigen; CyA: Cyclosporine;
MMF: Mycophenolate mofetil; AZA: Azathioprine; CNI: Calcineurin inhibitor.
BKV-related outcomes
Five-year patient (86.6% vs 88.7%, log-rank P = 0.8736) and overall graft (70.6% vs
80.2%, log-rank P = 0.1201) survival rates for patients with or without BKV viremia
were similar (Figure 3A and Figure 4A). However, the viremic group showed higher
5-year crude cumulative (22.5% vs  12.2%, Gray’s test P  = 0.0270) and 30-d-event-
censored (22.5% vs 7.1%, Gray’s test P = 0.001) incidences of graft failure than control
(Figure 5A and Figure 6A).
In the viremic group, higher proportions of recipients also experienced BPR or
impaired graft function (5-year MDRD eGFR < 30 mL/min) than the group without
viremia: 26/60, 43.3% vs 125/575, 21.7% (P = 0.0004) and 27/60, 45% vs 155/575, 27%
(P = 0.0064), respectively.
We could  not  find  any  significant  differences  between the  two groups  in  the
proportions of recipients with urinary leakage (viremia: 1/60, 1.7% vs  no viremia:
7/575,  1.2%,  P  =  0.5501)  or  ureteral  stenosis  (viremia:  2/60,  3.3% vs  no viremia:
11/575, 1.9%, P = 0.3520). Cumulative incidences of opportunistic infection, CMV
disease,  varicella-zoster  virus-associated  disease  (chickenpox  or  shingles),
malignancy, and NODAT were also comparable (data not shown).
Recipients  with BKV viremia had their  immunosuppressive therapy modified
according to the scheme described above. Response to treatment was complete in
33/60 (55%), partial in 16/60 (26.7%), and absent in 11/60 (18.3%) patients. Following
reduction of the net state of immunosuppression, 7/60 (11.7%) recipients developed
BPR.
To further investigate the specific impact of PVAN on transplant outcome, we
compared results of patients with or without nephropathy. Five-year patient survival
distributions for the two groups were equivalent (PVAN: 89.9% vs No PVAN: 88.4%,
log-rank P  = 0.913; Figure 3B). Five-year overall graft survival rate was better for
patients without PVAN but the difference did not reach statistical significance (80.1%
vs 66.5%, log-rank P = 0.077; Figure 4B). As depicted in Figure 5B and Figure 6B, the
PVAN group showed higher  5-year  crude  cumulative  and  30-d-event-censored
incidences of graft failures than control: 29.1% vs 12.1% (Gray’s test P = 0.008) and
29.1% vs 7.2% (Gray’s test P < 0.001), respectively.
PVAN was the  leading cause  of  transplant  loss  in  patients  with  BKV viremia
(PVAN: 11/18, 61.1% vs death with function: 4/18, 22.2% vs chronic allograft injury:
1/18, 5.6%) and the fourth in the entire study cohort (Figure 1).
Risk factors for BKV viremia and PVAN
Univariate analysis, based on chi-square or Fisher exact test for recipients with or
without BKV viremia are reported in Table 2. Variables with a P-value greater than 0.8
were not considered in the multivariable model building. This left 16 variables to be
studied. Among the 16 variables, the selected variables according to the backward
procedure were: Afro-Caribbean ethnicity, pre-transplant diabetes, PRA value > 50%,
CMV prophylaxis, HLA mismatching > 4, BPR within thirty days of transplant. The
final model is reported in Table 4. By repeating the backward variable selection in 500
bootstrap samples, it is worth noticing that the selected variables were also selected in
at least 60% of the bootstrap samples. Moreover recipient CMV IgG positive was
selected  in  68%  of  the  bootstrap  samples  and  recipient  cytomegalovirus  D+R-
immunization  in  60%  of  the  samples.  The  C-index  is  0.64  after  correction  for
optimism.
Univariate analysis, based on Chi-square or Fisher exact test for 60 recipients with
BKV  viremia,  classified  as  PVAN  positive  or  negative,  are  reported  in  Table  3.
Variables with a P-value greater than 0.5 were not considered in the multivariable
model building. This left 8 variables to be studied. It is worth noticing that initial
viremia ≥ 10000 copies/mL and sustained vs.  transient  viremia almost  perfectly
discriminated between patients with or without PVAN. The odds ratio contrasting
initial viremia ≥ 10000 vs < 10000 copies/mL is 54 (95%CI: 13-477) calculated using
Firth penalized logistic  regression with a C-index equal to 0.89.  Considering the
remaining variables, a backward selection procedure was performed. The selected
variables were: Afro-Caribbean ethnicity, cardiovascular disease, donor CMV IgG
positive, donor age ≥ 60 years. The final model is reported in Table 5. By repeating the
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Figure 1
Figure 1  Distribution of specific causes of kidney allograft loss in the study population. PVAN: Polyomavirus-
associated nephropathy.
backward variable selection in 500 bootstrap samples, only the 4 selected variables
were also selected in at least 50% of the bootstrap samples. The C-index is 0.62 after
correction for optimism.
DISCUSSION
The development of new and more powerful immunosuppressive agents has led to a
significant reduction of acute rejection rates after kidney transplantation[24].  As a
consequence, we have observed an impressive improvement in short- and mid-term
graft survival rates. However, long-term outcomes have only marginally improved[25].
Death  with  function,  chronic  allograft  injury,  and PVAN have  now emerged as
leading causes of premature transplant loss[25].  Viral  infections are a well  known
complication of chronic immunosuppression[26]. CMV and BKV are the most common
opportunistic  infections  in  renal  transplant  recipients[27].  Due  to  a  widespread
application of  systematic  protocols  for  the prevention and treatment  of  CMV in
immunocompromised hosts, remarkable results have been obtained[28]. Management
of BKV infection has been also evolving[14]. Nevertheless, clinical outcome of kidney
transplant recipients with PVAN remains sub-optimal[29].
In the present study we investigated incidence, risk factors, and long-term outcome
of BKV infection in a cohort of kidney transplant recipients managed according to an
aggressive screening and diagnostic protocol for PVAN. Effectiveness of a treatment
strategy based on a step by step reduction of the net state of immunosuppression was
also evaluated.
KDIGO guideline suggests  screening all  kidney transplant  recipients  for  BKV
replication with plasma qPCR at least monthly for the first six months and then every
three months until the end of the first post-transplant year[14]. As described above, we
performed a more intensive screening, especially during the first three months after
transplant.  We found an incidence of BKV viremia and PVAN of 9.5% and 6.5%,
respectively. More than half (55%) of the episodes of viremia were recorded within
180  d  of  transplant;  none  in  the  first  thirty  days.  These  results  are  in  line  with
previously published data[30-32] and support the recommendations of current clinical
guidelines. Indeed, our experience suggests that a more aggressive screening strategy,
at least in the very early post-transplant phase, may not be beneficial.
Despite a previous report demonstrating an association between onset of viremia
and histological evidence for nephropathy[32],  we could not find any relationships
between the  time  viremia  was  first  diagnosed and PVAN.  We did  observe  that
patients with an initial viral load ≥ 10000 copies/mL were more likely to develop
nephropathy and lose their graft due to BKV than recipients with lower viral loads.
An association between duration of the viremic phase and risk of PVAN or PVAN-
related graft loss was also demonstrated. Interestingly, no graft failures due to BKV
were recorded in patients with an initial viral load < 10000 copies/mL or with a viral
replication < 3 wk. Plasma qPCR is considered the most reliable test to monitor viral
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Figure 2
Figure 2  Crude cumulative incidence of BK-viremia in the study cohort considering death and graft failure as
competing events. BKV: BK-viremia.
replication and assess response to treatment[13]. Even though there is no established
viral load cut-off associated with PVAN, some authors have suggested that a viral
load > 4 log copies/mL may be predictive of nephropathy[33]. KDIGO guidelines also
recommend prompt reduction of immunosuppression in patients with a BKV viral
load > 10000 copies/mL[14]. Our data confirm the predictive ability of initial viral load
for the risk of PVAN and strongly support the use of 10000 copies/mL as a cut-off to
discriminate between low- and high-risk kidney transplant recipients. At the same
time, as a few cases of nephropathy have been observed in patients with an initial
viral load < 10000 copies/mL, we suggest other prognostic information such as the
duration of viremia to be considered along with initial viral load in the evaluation of
this specific subgroup of recipients.
Allograft histology is accepted as the gold standard for the diagnosis of PVAN[13].
Several grading systems are also available[34]. Most centres reserve transplant biopsy
for patients with high viral loads or unexplained deterioration of function. Such a
policy, whilst reasonable, does not take into account the aforementioned proportion of
patients with a low viral load and histological evidence of PVAN (15% in our series).
Since early diagnosis of nephropathy and reduction of immunosuppression have been
recognized as key factors for the prevention of BKV-related graft loss, we believe that
every patient with BKV viremia should be offered histological evaluation. For low-
risk recipients (initial viral load < 10000 copies/mL and duration of viral replication <
3 wk) or for patients more likely to develop biopsy-related complications, a non-
invasive test may represent a reasonable option. In this regard, interesting results
have been obtained using electron microscopy[35] and urine mRNA profiles[36].
Our treatment strategy for BKV infection followed recommendations by current
international guidelines[13,14]. Response to progressive reductions in the net state of
immunosuppression was observed in 82% of the patients. These results are overall
satisfactory but it is worth noting that among recipients with BKV infection, 27%
experienced  permanent  deterioration  of  function  (5-year  MDRD  eGFR  <  30
mL/min/1.73 m2) and 18% eventually lost their graft due to PVAN. Moreover, in line
with Park and colleagues[37], analyses of death-censored and 30-d-event-censored graft
survival rates showed inferior long-term outcome for patients with BKV infection
(regardless of nephropathy) than control. Compared with other reports[30,38,39], these
results are less encouraging and strongly advocate for further research on specific
anti-BKV treatment strategies.
Risk factors for BKV infection after kidney transplantation have been extensively
studied but  results  remain  inconsistent.  The  net  state  of  immunosuppression  is
currently  considered  the  most  important  determinant  of  BKV  infection  and
nephropathy[13].  Our multivariable model  showed that  Afro-Caribbean ethnicity,
donor-recipient HLA mismatch > 4, PRA test > 50%, and BPR within thirty days of
transplant  are  significant  predictor  of  BKV  infection.  It  also  showed  that  CMV
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Table 2  Characteristics of kidney recipients with or without BK-viremia
Variables
Median (IQR) or n (%)
P
No BKV group BKV group
Patients 569 60 -
Recipient Male : Female 333 : 236 39 : 21 0.4076
Caucasian ethnicity 255/569 (44.8) 24/60 (40) 0.4977
Afro-Caribbean ethnicity 94/569 (16.5) 20/60 (33.3) 0.0024
Recipient age (years) 47 (36-55) 48.5 (37-53.25) 0.7263
Recipient age ≥ 60 yr 74/569 (13) 10/60 (16.7) 0.4255
Recipient BMI ≥ 30 kg/m2 79/569 (13.9) 8/60 (13.3) 1.0000
Pre-transplant diabetes 77/569 (13.5) 6/60 (10) 0.5499
Pre-transplant cardiovascular disease 55/569 (9.7) 7/60 (11.7) 0.5473
Recipient CMV IgG positive 391/569 (68.7) 40/60 (66.7) 0.7707
Primary renal disease
Glomerular disease 167/569 (29.4) 18/60 (30)
Polycystic kidney disease 62/569 (10.9) 9/60 (15)
Tubular-interstitial nephropathy 77/569 (13.5) 4/60 (6.7)
Diabetic nephropathy 45/569 (7.9) 4/60 (6.7)
Hypertension 47/569 (8.3) 8/60 (13.3)
Unknown renal disease 130/569 (22.8) 11/60 (18.3)
Other renal disease 41/569 (7.2) 6/60 (10)
Haemodialysis 266/569 (46.7) 28/60 (46.7) 1.0000
Peritoneal dialysis 123/569 (21.6) 13/60 (21.7) 1.0000
Pre-emptive transplant 72/569 (12.7) 8/60 (13.3) 0.8395
Panel-reactive antibody test > 50% 83/569 (14.6) 18/60 (30) 0.0047
Primary transplant 497/569 (87.3) 53/60 (88.3) 1.0000
Deceased donor 357/569 (62.7) 38/60 (63.3) 1.0000
Donation after brain death donor 235/569 (41.3) 27/60 (45) 0.5848
ABO-incompatible transplant 21/569 (3.7) 4/60 (6.7) 0.2856
Donor age (yr) 47 (38-57) 51.5 (40.75-60.25) 0.0483
Donor age ≥ 60 yr 115/569 (20.2) 17/60 (28.3) 0.1808
Donor-recipient gender mismatch 308/569 (54.1) 32/60 (53.3) 1.0000
Donor CMV IgG positive 323/569 (56.8) 31/60 (51.7) 0.4947
Cytomegalovirus D+R- immunization 79/569 (13.9) 4/60 (6.7) 0.1582
Cold ischemia time (h) 12 (4-16) 12 (4-17.25) 0.9920
Cumulative HLA mismatch 3 (2-4) 3 (2-5) 0.0759
HLA mismatch > 4 76/569 (13.4) 16/60 (26.7) 0.0110
HLA-A mismatch 1 (1-2) 1 (1-2) 0.6079
HLA-B mismatch 1 (1-1) 1 (1-2) 0.1896
HLA-DR mismatch 1(0-1) 1 (0-1.25) 0.0482
Induction treatment
Anti-IL2-receptor antagonist 388/569 (68.2) 43/60 (71.7)
Rabbit anti-thymocyte globulin 156/569 (27.4) 13/60 (21.7)
Rituximab 21/569 (3.7) 4/60 (6.7)
Alemtuzumab 3/569 (0.5) 0/60 (0)
Muromonab-CD3 1/569 (0.2) 0/60 (0)
Maintenance immunosuppression
CyA-based scheme 385/569 (67.7) 40/60 (66.7)
Tacrolimus-based scheme 182/569 (32.0) 20/60 (33.3)
MMF-containing scheme 490/569 (86.1) 54/60 (90)
AZA-containing scheme 80/569 (14.1) 6/60 (10)
CNI-free scheme 2/569 (0.4) 0/60 (0)
Steroid-free scheme 13/569 (2.3) 1/60 (1.7)
Cytomegalovirus prophylaxis 224/569 (39.4) 17/60 (28.3) 0.1239
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DGF 152/569 (26.7) 15/60 (25) 0.8783
BPR within 30 d of transplantation 54/569 (9.5) 13/60 (21.7) 0.0073
BKV:  BK-virus;  IQR:  Interquartile  range;  BMI:  Body  mass  index;  CMV:  Cytomegalovirus;  IgG:
Immunoglobulin class G; HLA: Human leukocyte antigen; CyA: Cyclosporine; MMF: Mycophenolate mofetil;
AZA: Azathioprine; CNI: Calcineurin inhibitor; DGF: Delayed graft function; BPR: Biopsy-proven rejection.
prophylaxis reduces the risk of BKV infection.
Previous rejection is a well recognized risk factor for PVAN[40]. Renal injury arising
from  cellular  or  humoral  allograft-specific  immune  response  and  increased
immunosuppression can reasonably account for such an association.
The relationship between degree of HLA mismatching and BKV infection is less
clear[34]. The accepted explanation is that recipients with a higher mismatch are at
increased  risk  of  rejection  and  therefore  generally  receive  more  intensive
immunosuppressive protocols than patients with more favourable donor-recipient
matching[34]. BKV-specific immune response inability to control viral replication and
progression to nephropathy due an impaired HLA-restricted recognition of viral
antigens or protective effect of specific HLA antigens may also play a role[41].
We  found  that  a  pre-transplant  PRA  value  >  50%  increases  the  risk  of  BKV
infection. Pre-immunization is widely considered a strong determinant of rejection[42]
and transplant candidates with preformed anti-HLA antibodies are more likely to
receive antibody-removal therapies, lymphocyte-depleting agents, and high-dose
calcineurin  inhibitors  than  non-sensitized  patients.  Therefore,  the  increased
susceptibility to BKV infection observed in this group of recipients may be due to over
immunosuppression.
It has been reported that Caucasian recipients are at increased risk of PVAN[34]. In
contrast with a previous study[43] we found that Afro-Caribbean recipients were more
likely to experience BKV viremia than Caucasian. Moreover, our multivariable model
showed that Afro-Caribbean ethnicity was an independent risk factor for both BKV
viremia and PVAN. Comparisons between different ethnic groups are difficult to
explain  given  the  various  confounding  factors  such  as  seroprevalence  of  BKV
infection,  HLA phenotype,  risk of  rejection,  and access  to  care.  Recent  data also
demonstrate that transplant outcomes for patients with similar heritage may not be
translatable between different countries[44].  Taking into account all  these possible
limitations, it is plausible to speculate that the increased risk of BKV infection and
PVAN observed in our Afro-Caribbean recipients may be at least partially related to
the increased amount of immunosuppression they generally receive compared to
other ethnicities[45].
CMV is a major cause of post-transplant morbidity and mortality[46]. Similarly to
BKV,  immunosuppression  is  considered  the  strongest  risk  factor  for  CMV
reactivation.  A  possible  interaction  between  CMV  and  BKV  has  been  already
postulated.  However,  the  existence  of  an  epidemiological  association  remains
debated[47,48]. It is also still unclear whether CMV infection has a protective effect on
BKV reactivation[48]. As was recently shown by Blazquez-Navarro and colleagues[27],
our data indirectly support the hypothesis that CMV infection may rather favour BKV
replication. CMV prophylaxis has been demonstrated to reduce the incidence of CMV
infection during the first six-twelve months after transplant[46].  Therefore, we can
reasonably  speculate  that  the  lower  risk  of  BKV  infection  observed  in  patients
receiving CMV prophylaxis may be due to a lower incidence of sub-clinical CMV
reactivations.
This is one of the largest single-centre observational study investigating incidence,
risk factors, and outcomes of BKV infection after kidney transplantation. We confirm
previously reported epidemiological data and support systematic screening, early
histological evaluation, and prompt reduction of the net state of immunosuppression
for the prevention of PVAN and BKV-related graft  failure.  At the same time, we
highlight the limitations of current treatment modalities and the need for proper
antiviral therapies. An initial plasma viral load ≥ 10000 copies/mL is the strongest
determinant of sustained viral replication, PVAN, and graft loss. In addition to other
well recognized risk factors,  we identified a PRA test > 50% and Afro-Caribbean
ethnicity as independent predictors of BKV infection. A protective effect of CMV
prophylaxis has been also suggested. Properly designed large multi-centre studies are
warranted to further investigate specific risk factors for PVAN and alternative anti-
BKV strategies.
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Table 3  Characteristics of kidney recipients with BK-viremia and negative (No polyomavirus-associated nephropathy group) or positive
allograft histology (Polyomavirus-associated nephropathy group)
Variables
Median (IQR) or n (%)
P
No PVAN group PVAN group
Patients 20 40
Recipient Male : Female 13 : 7 26 : 14 1.0000
Caucasian ethnicity 9/20 (45) 15/40 (37.5) 0.5896
Afro-Caribbean ethnicity 4/20 (20) 16/40 (40) 0.1536
Recipient age (yr) 49 (33.5-58) 48.5 (37.75-53) 0.8887
Pre-transplant diabetes 1/20 (5) 5/40 (12.5) 0.6532
Pre-transplant CVD 4/20 (20) 3/40 (7.5) 0.2077
Recipient CMV IgG positive 13/20 (65) 27/40 (67.5) 1.0000
Haemodialysis 9/20 (45) 19/40 (47.5) 1.0000
Peritoneal dialysis 6/20 (30) 7/40 (17.5) 0.3258
Pre-emptive transplant 2/20 (10) 6/40 (15) 0.7068
PRA test > 50% 6/20 (30) 12/40 (30) 1.0000
Primary transplant 17/20 (85) 36/40 (90) 0.6763
Deceased donor 13/20 (65) 25/40 (62.5) 1.0000
ABO-incompatible transplant 1/20 (5) 3/40 (7.5) 1.0000
Donor age (yr) 53.5 (42.25-62.75) 51 (40.75-57) 0.30302
Donor age ≥ 60 yr 8/20 (40) 9/40 (22.5) 0.2246
Donor CMV IgG positive 7/20 (35) 24/40 (60) 0.1004
CMV D+R- immunization 1/20 (5) 3/40 (7.5) 1.0000
Cold ischemia time (h) 14.25 (4.3-21.5) 12 (4-15) 0.4413
Cumulative HLA mismatch 3 (3-4.25) 3 (2-5) 0.4654
HLA mismatch > 4 5/20 (25) 11/40 (27.5) 1.0000
HLA-A mismatch 1 (1-1.25) 1 (1-2) 0.78716
HLA-B mismatch 1 (1-2) 1 (1-2) 0.25014
HLA-DR mismatch 1 (0-1.25) 1 (0-1.25) 0.8181
Induction immunosuppression
Anti-IL2-receptor antagonist 15/20 (75) 28/40 (70)
Anti-thymocyte globulin 4/20 (20) 9/40 (22.5)
Rituximab 1/20 (5) 3/40 (7.5)
Maintenance immunosuppression
CyA-based scheme 14/20 (70) 26/40 (65)
Tacrolimus-based scheme 6/20 (30) 14/40 (35)
MMF-containing scheme 19/20 (95) 35/40 (87.5)
AZA-containing scheme 1/20 (5) 5/40 (12.5)
CNI-free scheme 0/20 (0) 0/40 (0)
Steroid-free scheme 0/20 (0) 1/40 (2.5)
CMV prophylaxis 4/20 (20) 13/40 (32.5) 0.3752
DGF 6/20 (30) 9/40 (22.5) 0.5424
BPR within 30 d of transplant 4/20 (20) 9/40 (22.5) 1.0000
Initial viremia ≥ 10000 copies/mL 3/20 (15) 37/40 (92.5) < 0.00001
Initial viral load (copies/mL) 6000 (2975-7550) 134800 (28750-425000) < 0.00001
BKV viremia ≥ 3 wk 5/20 (25) 38/40 (95) < 0.00001
PVAN: Polyomavirus-associated nephropathy; IQR: Interquartile range; BMI: Body mass index; CVD: Cardiovascular disease; CMV: Cytomegalovirus;
IgG: Immunoglobulin class G; PRA: Panel-reactive antibody; HLA: Human leukocyte antigen; CyA: Cyclosporine; MMF: Mycophenolate mofetil; AZA:
Azathioprine; CNI: Calcineurin inhibitor; DGF: Delayed graft function; BPR: Biopsy-proven rejection.
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Table 4  Final multivariable model for the risk of BK-viremia in a cohort of kidney transplant recipients
Variable OR 95%CI P
Afro-Caribbean ethnicity 2.882 1.549; 5.259 0.001
Panel-reactive antibody > 50% 3.352 1.737; 6.338 < 0.001
HLA mismatch > 4 2.585 1.303; 4.955 0.005
CMV Prophylaxis 0.467 0.244; 0.854 0.017
BPR within 30 d of transplant 2.342 1.117; 4.664 0.019
Table 5  Final multivariable model for the risk of Polyomavirus-associated nephropathy in a cohort of kidney transplant recipients
Variable OR 95%CI P
Afro-Caribbean ethnicity 2.717 0.705-12.458 0.164
Cardiovascular disease 0.235 0.034-1.42 0.117
Donor Age ≥ 60 yr 0.243 0.055-0.949 0.048
Recipient CMV IgG positive 4.371 1.261-17.968 0.027
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Figure 3
Figure 3  Kaplan-Meier patient survival curves. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant
recipients with (dashed line) or without (continuous line) polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.
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Figure 4
Figure 4  Kaplan-Meier overall graft survival curves. A: kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant
recipients with (dashed line) or without (continuous line) Polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.
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Figure 5
Figure 5  Crude cumulative incidence of graft failure considering death as a competing risk. A: kidney transplant recipients with (dashed line) or without
(continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line) Polyomavirus-associated nephropathy. BKV: BK-viremia;
PVAN: Polyomavirus-associated nephropathy.
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Figure 6
Figure 6  Crude cumulative incidence of graft failure considering death as a competing risk and excluding any events within thirty days of transplant. A:
kidney transplant recipients with (dashed line) or without (continuous line) BK-viremia; B: kidney transplant recipients with (dashed line) or without (continuous line)
Polyomavirus-associated nephropathy. BKV: BK-viremia; PVAN: Polyomavirus-associated nephropathy.
ARTICLE HIGHLIGHTS
Research background
Polyomavirus-associated nephropathy (PVAN) is  recognized as  a  leading cause of  kidney
allograft  loss.  Current  antiviral  therapies  offer  limited results.  Clinical  guideline suggests
periodic screening for BK-virus replication in blood and recommends prompt reduction of the
net state of immunosuppression in case of viremia. However, long-term outcome of kidney
transplant recipients with BK-virus infection remains sub-optimal.
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Research motivation
The development of new and more powerful immunosuppressive agents has led to a significant
reduction of  acute rejection rates after  kidney transplantation.  As a consequence,  we have
observed an impressive improvement in short- and mid-term graft survival rates but long-term
results have only marginally improved. BK-virus is one of the most common opportunistic
infection in renal transplant recipients and has been demonstrated to have a deleterious impact
on allograft function and survival. Management of BK-virus infection has significantly changed
and encouraging results  have been obtained.  Nevertheless,  long-term data  are  scarce  and
previously published reports may not reflect current clinical practice. Therefore, we performed
an observational study to investigate incidence, risk factors, and long-term outcome of BK-virus
infection  in  a  cohort  of  kidney  transplant  recipients  managed according  to  an  aggressive
screening and diagnostic protocol for PVAN. Effectiveness of a treatment strategy based on a
step by step reduction of the net state of immunosuppression was also evaluated.
Research objectives
The aim of the present study was to evaluate incidence, risk factors, and outcome of BK-virus
infection after kidney transplantation.
Research methods
This single-centre observational study with a median follow up of 5 years was conducted in a
National  Health Service hospital  in UK and comprises 629 consecutive adult  patients who
underwent kidney transplantation between 2007 and 2013. Data were prospectively recorded
and annually reviewed until 2016. Recipients were periodically screened for BK-virus by plasma
quantitative polymerized chain reaction. Patients with BK plasma viral load ≥ 1000 copies/mL
were diagnosed BK-viremia and underwent histological assessment to rule out nephropathy. In
case of BK-viremia, immunosuppression was minimized according to a prespecified protocol.
The following outcomes were evaluated: patient survival, overall graft survival, graft failure
considering death as a competing risk, 30-d-event-censored graft failure, response to treatment,
rejection, renal function, urologic complications, opportunistic infections, new-onset diabetes
after transplantation, and malignancies. We used a multivariable model to analyse risk factors
for BK-viremia and nephropathy.
Research results
BK-viremia and PVAN were detected in 9.5% and 6.5% of the study population, rspectively.
Patients  with  initial  plasma viral  load ≥  10000  copies/mL were  more  likely  to  experience
sustained viremia (95% vs 25%, P < 0.00001), nephropathy (92.5% vs 15%, P < 0.00001), and
polyomavirus-related graft loss (27.5% vs. 0%, P = 0.0108) than recipients with low initial plasma
viral load. Recipients with viremia showed higher 5-year crude cumulative (22.5% vs 12.2%, P =
0.0270) and 30-d-event-censored (22.5% vs  7.1%, P  = 0.001) incidences of graft  failure than
control. In the viremic group we also observed higher proportions of recipients with 5-year
estimated glomerular filtration rate < 30 mL/min than the group without viremia: 45% vs 27%
(P = 0.0064). Response to treatment was complete in 55%, partial in 26.7%, and absent in 18.3%
patients. The PVAN group showed higher 5-year crude cumulative and 30-d-event-censored
incidences of graft failure than control: 29.1% vs 12.1% (P = 0.008) and 29.1% vs 7.2% (P < 0.001),
respectively. Afro-Caribbean ethnicity, panel-reactive antibody > 50%, human leukocyte antigen
mismatching > 4, and rejection were independent risk factors for BK-virus viremia whereas
cytomegalovirus prophylaxis was protective.
Research conclusions
As recommended by most recent international clinical guideline, our study supports systematic
screening,  early  histological  evaluation,  and  prompt  reduction  of  the  net  state  of
immunosuppression for the prevention of  PVAN and BK-related graft  failure after kidney
transplantation.  Nevertheless,  we  also  demonstrated  the  limitations  of  current  treatment
strategies and the need for more specific antiviral therapies. In particular, we showed that both
BK-viremia  and nephropathy negatively  affect  long-term graft  function  and survival.  We
confirmed that an initial plasma viral load ≥ 10000 copies/mL is the strongest determinant of
sustained viral replication, PVAN, and graft loss. We identified a PRA test > 50% and Afro-
Caribbean ethnicity as independent predictors of BK-virus infection. Our data also suggest a
protective effect of cytomegalovirus prophylaxis on BK-virus replication.
Research perspectives
Our study represents one of the largest observational study on BK-virus infection in kidney
transplant recipients. We managed to confirm our preliminary hypothesis and demonstrated
that despite aggressive screening and treatment strategies, long-term outcome for patients with
BK-virus infection remain consistently inferior than control. We identified new risk factors for
BK-viremia but larger populations are needed to further investigate risk factors for PVAN. In
order to improve results, future research should be focusing on alternative prognostic markers,
non-invasive diagnostic tests, and novel antiviral therapies. Properly designed multi-centre
prospective randomized clinical trials are warranted.
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